SESSION TYPE: ILD - Bench to Bedside
PRESENTED ON: Wednesday, October 24, 2012 at 02:45 PM - 04:15 PM
PURPOSE: Various cytokines are believed to influence the pathogenesis of IPF and NSIP, yet correlations between these and disease severity have not been well characterized. Insight into these relationships may shed light on disease pathogenesis. We aimed to evaluate the relationship of serum cytokines to PFTs in a cohort with IPF or NSIP.
METHODS: Patients with IPF or NSIP seen within the Advanced Lung Disease Program were identified. Fasting blood was collected to measure levels of 20 cytokines via Bio-Plex Suspension Array System (Bio-Rad Laboratories, Inc., Hercules, CA) and correlated to disease severity based on approximate tertiles of the FVC% predicted.
RESULTS: There were 32 patients in whom PFTs and blood sample data were evaluated. Of these, 34% were female, the mean age was 62 ± 9 years, and 56% had IPF. Tertiles of %FVC predicted were defined as severe disease (30-48, n=11), mild disease (51-64, n=10) and moderate disease (65-96, n=11). No significant differences between FVC% tertiles were observed with respect to diagnosis, age, gender or BMI. Significant differences in the following cytokines were observed amongst the groups: Tertile classification revealed, severe %FVC (30-48, n=11), moderate %FVC (51-64, n=10) and mild %FVC (65-96, n=11). Eotaxin levels for tertiles were: [severe (270.20±97.66), moderate (208.13±76.29), mild (133.42±58.52), p=.003]. Rantes: [severe (9459.94±615.67), moderate (7714.04±1459.88), mild (6955.94±1900.98), p=.005]. MCP-1: [severe (108.84±63.88), moderate (55.10±18.76), mild (39.90±12.98), p=.003]. IL-2 was also slightly significant [severe (31.38±24.47), moderate (12.76±7.14), mild (13.36±9.57), p=.046].
CONCLUSIONS: The correlation between Eotaxin, Rantes, MCP-1 and IL-2 and disease severity suggests their role in influencing or reflecting disease severity.
CLINICAL IMPLICATIONS: This avenue of research may provide biomarkers for long term monitoring of disease and potentially might help identify targets for therapy.
DISCLOSURE: The following authors have nothing to disclose: Anthony Loria, Mary Smith, Nargues Weir, Shahzad Ahmad, Steven Nathan
No Product/Research Disclosure InformationInova Advanced Lung Disease and Transplant Program, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA